John F. Neylan is Chief Medical Officer at KERYX BIOPHARMACEUTICALS INC (KERX). They have made 23 open-market trades across 2 companies since 2015, most recently 2021-12-20.
CIK 0001640447
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $62K since 2015, against 22 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ANGN | SELL · 10b5-1 | 2021-12-20 | 2021-12-21 | $2.62 | $938 | +8.6% | -17.8% | -19.7% |
| ANGN | SELL · 10b5-1 | 2021-11-18 | 2021-11-22 | $4.13 | $2K | -17.5% | -34.6% | -49.1% |
| ANGN | SELL · 10b5-1 | 2021-10-18 | 2021-10-20 | $8.62 | $3K | -43.8% | -51.7% | -73.6% |
| ANGN | SELL · 10b5-1 | 2021-09-20 | 2021-09-21 | $10.07 | $4K | -0.6% | -13.2% | -73.8% |
| ANGN | SELL · 10b5-1 | 2021-08-18 | 2021-08-19 | $9.03 | $3K | +14.7% | +2.8% | -55.8% |
| ANGN | SELL · 10b5-1 | 2021-07-21 | 2021-07-22 | $10.98 | $4K | -0.2% | -8.4% | -22.7% |
| ANGN | SELL · 10b5-1 | 2021-06-18 | 2021-06-21 | $13.20 | $5K | -5.3% | -11.4% | -24.7% |
| ANGN | SELL · 10b5-1 | 2021-05-18 | 2021-05-19 | $13.91 | $5K | -1.8% | -10.1% | -37.6% |
| ANGN | SELL · 10b5-1 | 2021-04-19 | 2021-04-20 | $13.55 | $5K | +7.0% | +21.7% | -18.7% |
| ANGN | SELL | 2021-03-17 | 2021-03-19 | $19.13 | $8K | +1.5% | -23.8% | -25.1% |
| KERX | SELL | 2018-11-15 | 2018-11-16 | $2.77 | $3K | +2.1% | N/A | N/A |
| KERX | SELL | 2018-10-29 | 2018-10-30 | $3.07 | $4K | +11.0% | +1.7% | N/A |
| KERX | SELL | 2018-08-15 | 2018-08-16 | $3.04 | $4K | +11.6% | -1.0% | -8.3% |
| KERX | SELL | 2018-07-30 | 2018-07-31 | $3.86 | $5K | -22.5% | -21.0% | -32.2% |
| KERX | SELL | 2018-05-15 | 2018-05-16 | $5.69 | $7K | -8.4% | -13.6% | -46.4% |
| KERX | SELL | 2018-04-30 | 2018-05-01 | $4.67 | $6K | +23.1% | +16.9% | -8.2% |
| KERX | SELL | 2018-04-23 | 2018-04-24 | $4.59 | $5K | +1.1% | +9.9% | -5.3% |
| KERX | SELL | 2018-02-15 | 2018-02-16 | $4.81 | $27K | -6.4% | -10.0% | +17.4% |
| KERX | SELL | 2018-01-29 | 2018-01-31 | $4.81 | $7K | -2.2% | +3.0% | -1.1% |
| KERX | SELL | 2018-01-23 | 2018-01-24 | $4.92 | $7K | -3.6% | +9.0% | -1.9% |
| KERX | SELL | 2017-10-30 | 2017-10-31 | $6.03 | $8K | -26.3% | -26.9% | -25.3% |
| KERX | SELL | 2017-10-23 | 2017-10-24 | $6.53 | $8K | +9.8% | -16.7% | -14.0% |
| KERX | SELL | 2017-07-31 | 2017-08-01 | $7.14 | $10K | -8.3% | +3.0% | -11.1% |
| KERX | SELL | 2017-07-24 | 2017-07-25 | $7.27 | $9K | -6.3% | -7.5% | -18.5% |
| KERX | SELL | 2017-05-01 | 2017-05-03 | $5.97 | $9K | +4.8% | +4.2% | +12.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.